U.S. Hemophilia Physician Prescribing Practices: Then and Now

Brenda Riske, University of Colorado Denver; Marion Koerper, Prof Emerita, Univ of CA, SF; Judith Baker, University of California Los Angeles; Megan Ullman, University of Texas Houston; Randall Curtis, Factor VIII Computing

INTRODUCTION

U.S. hemophilia treatment costs may approach $500,000/person/year, most of which is attributable to the cost of factor concentrate. Given these high costs, in the era of new and more expensive therapies, examining variances in physician treatment practices for persons with hemophilia is vital. Scant published multicenter data documenting prescribing practices among U.S. physicians are available. In the current healthcare environment of personalized medicine using individualized therapeutic approaches, a study detailing prescribing differences over time may inform current use of expensive hemophilia treatment products in the United States.

OBJECTIVE

To understand trends in US physician prescribing practices for hemophilia.

METHODS

Data from self-administered paper surveys using convenience samples of clinicians attending major national hematology conventions in 1999 and 2015 were analyzed. In 1999, 40 physicians completed surveys, and 53 physicians completed them in 2015. Comparisons were made between the two groups. Surveys were de-identified, although respondents from 2015 could elect to provide contact information to receive the results. Both groups treated pediatric and adult patients but detailed demographics are not available for the 1999 respondents. Prescribing practices were for both Hemophilia A (HA) and Hemophilia B (HB).

RESULTS

Demographic data for respondents were not collected for the 1999 survey. Number of respondents in 1999 = 40 and in 2015 N = 53. Table 1 (2015 data only) demonstrates 6 respondents provided pediatric only care, 2 provided adult only care and 46 provided care to both. Data also includes relative size of patient population served. In comparing treatment regimens between the different time periods, Table 2 shows that dosing for HA and HB increased between 1999 and 2015. In 1999, in HB, only 21% prescribed >40 units/kg compared to more than 50% in the 2015 respondents. Table 3 shows that ITI was prescribed 70% of the time in pediatrics compared to 2015 when more than 85% prescribed pediatric ITI for 75 – 100% of the time. The same trend holds true for pediatric primary prophylaxis for patients <4 years of age. In 1999, about 40% prescribe prophylaxis 50 – 75% which is substantially lower than in 2015 when over 90% prescribed primary prophylaxis from 75 -100% of the time. Secondary prophylaxis is prescribed from ½ - all time by 60% in 1999 and 57% in 2015. Data on prescribing practices for surgical procedures was not collected in 1999 but in 2015, treatment in HA patients ranged from 8 - >40 days post-operatively. For port placements in patients with HA, greater than 2/3 of respondents prescribed 7 days of treatment and 9% prescribed more than 21 days.

CONCLUSIONS

During the past 15 years, the amount of factor prescribed for major and minor bleeding episodes has increased both Hemophilia A and B. Both surveys neglected to define “routine” bleeding but defined “major” as CNS, Upper GI, and major trauma. ITI for both pediatric and adult patients was prescribed much more frequently in 2015 than in 1999. A similar trend of increased prophylaxis use in 2015 was observed, probably attributable to the publication of data from the Joint Outcome Study (Manco-Johnson, et al, 2007 N Engl J Med). Wide variances in duration of treatment following surgical procedures indicate the need for outcome measures that facilitate standardization of prescribing practices.

ACKNOWLEDGEMENTS

The authors would like to thank the American Society of Hematology and the Hemophilia Research Society for providing venues for collecting data in 1999. The Hemostasis and Thrombosis Research Society provided a similar venue for collection of the 2015 data. We sincerely thank all participants who completed the survey.